| Parameter | Reference omalizumab | Biosimilar (–20%) | Biosimilar (–30%) | Biosimilar (–50%) |
|---|---|---|---|---|
| Cost for 4 weeks (€) * | 745 | 596 | 522 | 372 |
| Estimated annual cost per patient (€) | 9,685 | 7,750 | 6,780 | 4,840 |
| Estimated annual savings per patient (€) | - | 1,935 | 2,905 | 4,840 |
| Relative saving | - | 20% | 30% | 50% |
* Assuming standard CSU dosing of 300 mg every 4 weeks (13 administrations/year). Values represent illustrative scenarios derived from published European pharmacoeconomic analyses and currently available pricing information. Actual prices and healthcare savings may vary depending on national procurement systems, reimbursement policies, market competition, and local tender procedures.
AS: Conceptualization, Writing—original draft. EN and CD: Conceptualization, Investigation, Supervision. MC and GWC: Validation, Writing—review & editing. All authors read and approved the submitted version.
Eustachio Nettis, who is an Editorial Board Member, and Giorgio Walter Canonica, who is Editor-in-Chief of Exploration of Asthma & Allergy, were not involved in the peer review or editorial decision-making process for this manuscript. Giorgio Walter Canonica reports having received research grants and/or lecturer or advisory board fees from A. Menarini, AstraZeneca, Celltrion, Chiesi Farmaceutici, Faes, Firma, Genentech, GrandPharma, Guidotti, GlaxoSmithKline, HAL Allergy, Novartis, OM Pharma, Organon, RedMaple, Sanofi-Genzyme, Stallergenes Greer, and Uriach Pharma. The remaining authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2026.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.